Full Text View
Tabular View
No Study Results Posted
Related Studies
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
This study has been withdrawn prior to recruitment.
Study NCT00319332   Information provided by GlaxoSmithKline
First Received: April 26, 2006   Last Updated: January 24, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Large-Cell, Follicular
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Large B-Cell, Diffuse
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Ibritumomab Tiuxetan
Iodine I 131 Tositumomab
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Iodine
Iodine-131 anti-B1 antibody
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Infective Agents, Local
Antineoplastic Agents
Growth Substances
Immunologic Factors
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services